Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors.

MLA

Dimopoulos, M. A., et al. “Treatment of Waldenstrom’s Macroglobulinemia Resistant to Standard Therapy with 2-Chlorodeoxyadenosine: Identification of Prognostic Factors.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 6, no. 1, Jan. 1995, pp. 49–52. EBSCOhost, https://doi.org/10.1093/oxfordjournals.annonc.a059040.

APA

Dimopoulos, M. A., Weber, D., Delasalle, K. B., Keating, M., & Alexanian, R. (1995). Treatment of Waldenstrom’s macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 6(1), 49–52. https://doi.org/10.1093/oxfordjournals.annonc.a059040

Chicago

Dimopoulos, M A, D Weber, K B Delasalle, M Keating, and R Alexanian. 1995. “Treatment of Waldenstrom’s Macroglobulinemia Resistant to Standard Therapy with 2-Chlorodeoxyadenosine: Identification of Prognostic Factors.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 6 (1): 49–52. doi:10.1093/oxfordjournals.annonc.a059040.